TNFRSF8 and diffuse large B-cell lymphoma: However, randomized evidence is needed to define the additive efficacy of BV to CHP, particularly in the setting of CD30- patients, as standard R-CHOP remains highly effective in DLBCL and even in PMLBCL [91].